Anti‐tumour necrosis factor (TNF)‐α therapy (etanercept) down‐regulates serum matrix metalloproteinase (MMP)‐3 and MMP‐1 in rheumatoid arthritis

Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Rheumatology (Impact Factor: 4.44). 06/2002; 41(5):484-9. DOI: 10.1093/rheumatology/41.5.484
Source: PubMed

ABSTRACT Matrix metalloproteinases (MMPs) are cytokine-modulated enzymes that play an important role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and cartilage destruction. This study evaluated the modulation of serum and synovial MMPs and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1, by therapy with soluble tumour necrosis factor (TNF) alpha receptor (etanercept).
Serum samples were collected from 60 RA patients at baseline and after 8 or 12 weeks of treatment. Paired synovial biopsies were obtained from 11 patients at two time points, before and after 8 weeks of treatment. We measured serum levels of MMP-1, MMP-3 and TIMP-1 by ELISA. Immunohistological analysis of synovial tissue was performed using monoclonal antibodies specific for MMP-1, MMP-3 and TIMP-1.
Etanercept therapy significantly down-regulated serum levels of MMP-3 and MMP-1 in parallel with the reduction in inflammatory parameters (C-reactive protein concentration and erythrocyte sedimentation rate) in RA patients. Baseline pretreatment serum levels of MMP-3 correlated with changes in clinical disease activity during therapy. No consistent changes in serum level of TIMP-1 were observed, while ratios of MMP-1 and MMP-3 to TIMP-1 were down-regulated following etanercept treatment. Immunohistochemical analyses revealed great interindividual variability, with generally a high level of expression of MMP and low expression of TIMP. No significant change in the pattern or number of positive cells occurred during therapy.
In RA patients, etanercept therapy down-regulates serum levels of MMP-3 and MMP-1 and the ratio between MMPs and TIMP-1. This may be an important mechanism for the prevention of future development of joint damage.

  • Source
    • "TNF-alpha inhibition reduces the cellularity of inflamed tissues, inhibits expression of proinflammatory cytokines including IL-1β, Il-6, Il-8 and GM-CSF, growth factors VEGF and chemokines such as MCP-1, all of which contribute to atherosclerosis. Inhibition also reduces TNFalpha induced expression of matrix metalloproteinases (MMPs), MMP-1 and MMP-3 (Catrina et al., 2002). This reduction in MMPs has the potential to reduce collagen degradation and increase the stability of atherosclerotic lesions (Aikawa et al., 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is the largest cause of morbidity and premature mortality and its major underlying pathology is atherosclerosis. Atherosclerosis commences with the deposition of lipids in the artery wall due to trapping by proteoglycans. Trapped lipoproteins are chemically and enzymatically modified to yield pro-inflammatory species that induce adhesion molecule expression on endothelial cells leading to the recruitment of multiple species of immune cells and a chronic inflammatory response. Ongoing remodelling of the vessel and later morphological changes generate "vulnerable" plaques, the acute rupture of which generates the clinical event. The major medical therapies are anti-hypertensives and lipid lowering agents. Although these therapies are amongst the most efficacious in cardiovascular medicine, in optimised well-controlled clinical trials the maximum effect is limited to an approximately 30% reduction in cardiovascular events. Hence, a huge burden of disease remains refractory to current therapies and atherosclerosis and its sequelae persist as a therapeutic target of immense importance. Potential therapeutic targets include the proteoglycan: lipoprotein interaction in the vessel wall, circulating and vessel wall associated atherogenic lipid species and the immune system. Anti-inflammatory therapies include specific cytokine antagonists and cytokine neutralizing antibodies, specific immune cell depleting antibodies and cell therapies using antigen specific regulatory T-cells and regulatory B-cells. In this review, we describe the process of atherosclerosis as it involves the role of chronic inflammation in the development and progression of atherosclerotic plaques and then the manner in which some of these inflammatory processes represent therapeutic targets.
    Pharmacology [?] Therapeutics 04/2011; 131(3):255-68. DOI:10.1016/j.pharmthera.2011.04.001 · 7.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The tumor necrosis factor (TNF) antagonists (anti-TNF biologics) infliximab (IFX), adalimumab (ADA), and etanercept (ETN) are commonly used worldwide for rheumatoid arthritis (RA), have produced clinical improvement in signs and symptoms, disability, and quality of life, and have significantly inhibited the progression of joint damage in early and long-standing disease. However, although anti-TNF biologics often induce rapid clinical improvement in patients with RA, 20–40% of RA patients show little or no clinical response. To maximize the clinical response to these agents, the mechanism underlying the variable response in individual patients must be understood; furthermore, a strategy is needed to predict responders and non-responders. Recently, several reports have demonstrated that cytokines and chemokines seem to be important and sensitive mediators in RA patients treated with anti-TNF biologics. We showed that serum CX3CL1 levels were decreased in response to IFX treatment, whereas there were no significant and uniform alterations after IFX treatment in other chemokines that have crucial roles in the pathogenesis of RA development. In addition, the most interesting result in the present study was that the lack of response in the active RA group despite treatment with IFX could be related to higher basal levels of CX3CL1 and its receptor, CX3CR1. In conclusion, the CX3CL1/CX3CR1 axis and other chemokine receptors, such as CCR3 and CCR5, in patients with active RA may be sensitive to anti-TNF therapy. These results also suggest that basal serum CX3CL1 levels correlate with the responsiveness of RA patients to IFX therapy.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the thesis was to investigate the significance of serum MMP-3 in relation to disease activity, and in particular in relation to radiological progression, in patients with early RA. The data were derived from a prospective follow-up study in patients with recent onset RA (disease symptoms < 1 year).
Show more

Full-text (2 Sources)

Available from
Nov 7, 2014